Needham & Company analyst Mike Matson reiterated a Buy rating and raised his price target on Zimmer Holdings (NYSE: ZMH) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Zimmer (ZMH) /Biomet Deal Viewed as 'Relatively Fair' - Deutsche BankApril 24, 2014 10:35 AM Zimmer's Biomet Deal Sparks Consolodation in OrthopedicsApril 24, 2014 9:07 AM Zimmer's (ZMH) Biomet Takeover Could Put Pressure on Rivals to MergeApril 24, 2014 8:38 AM Zimmer (ZMH) to Acquire Biomet in ~$13.35B DealApril 24, 2014 7:04 AM